ropivacaine HCl.
Phase 3Small molecule
Shanghai Hengrui Pharmaceutical Co., Ltd.ropivacaine HCl. is one of 59 small molecule programs targeting Hemorrhoid. It is currently in Phase 3.
3
Indications
5
Total Trials
1
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Ketalar
AAultman Health Foundation
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Marcaine
IInnocoll
Approved
Nitrostat
VViatris Specialty LLC
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Kenalog
BBassett Healthcare
Approved
Decadron
AAspen Global Incorporated
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hemorrhoid2 trials
Ropivacaine1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ropivacaine HCl.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details